Company Description
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-α4β7 and anti-TL1A mAbs; SPY130, a combination anti-α4β7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs.
The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023.
The company was incorporated in 2013 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Apr 7, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Cameron Turtle |
Contact Details
Address: Building 23, Suite 105 Waltham, Massachusetts 02453 United States | |
| Phone | 617 651 5940 |
| Website | spyre.com |
Stock Details
| Ticker Symbol | SYRE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001636282 |
| CUSIP Number | 00773J202 |
| ISIN Number | US00773J2024 |
| Employer ID | 46-4312787 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cameron Turtle DPHIL, Ph.D. | Chief Executive Officer and Director |
| Scott L. Burrows | Chief Financial Officer |
| Dr. Sheldon Sloan M.B.E., M.D. | Chief Medical Officer |
| Dr. Janet Gunzner-Toste M.B.A., Ph.D. | Senior Vice President of Operations |
| Brian Connolly | Chief Technical Officer |
| Eric McIntyre | Vice President of Finance and Investor Relations |
| Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer and Corporate Secretary |
| James Myers | Vice President of Quality and Compliance |
| Dr. Justin LaFountaine Ph.D. | Senior Vice President of Corporate Development |
| Melissa Cooper | Senior Vice President of People |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 4, 2026 | EFFECT | Notice of Effectiveness |
| Mar 3, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Feb 27, 2026 | EFFECT | Notice of Effectiveness |
| Feb 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Feb 19, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 19, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 19, 2026 | 8-K | Current Report |
| Feb 19, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |